GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Adicon Holdings Ltd (HKSE:09860) » Definitions » Notes Receivable

Adicon Holdings (HKSE:09860) Notes Receivable : HK$0 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Adicon Holdings Notes Receivable?

Adicon Holdings's Notes Receivable for the quarter that ended in Dec. 2023 was HK$0 Mil.


Adicon Holdings Notes Receivable Historical Data

The historical data trend for Adicon Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicon Holdings Notes Receivable Chart

Adicon Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - -

Adicon Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial - - - - -

Adicon Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Adicon Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Adicon Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicon Holdings (HKSE:09860) Business Description

Traded in Other Exchanges
Address
No. 208, Zhenzhong Road, West Lake, Zhejiang, Hangzhou, CHN
Adicon Holdings Ltd is one of the top three independent clinical laboratory or ICL, service providers in China. The company offers comprehensive and best-in-class testing services primarily to hospitals and health check centers through an integrated network of 33 self-operated laboratories across China. The high quality of its services is backed by its strong performance in terms of international accreditation and comprehensive testing menu. Its testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests. It has three major service platforms. Among them, the inspection service platform consists of clinical, pathology, reproductive genetic, genetic, and mass spectrometry laboratories.
Executives
Cap V General Partner, L.p. 2201 Interest of corporation controlled by you
Cap V, L.l.c. 2201 Interest of corporation controlled by you
Carlyle Asia Partners V, L.p. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii Gp L.l.c. 2201 Interest of corporation controlled by you
Carlyle Holdings Ii L.l.c. 2201 Interest of corporation controlled by you
Cg Subsidiary Holdings L.l.c. 2201 Interest of corporation controlled by you
Pearl Group Limited 2101 Beneficial owner
Tc Group Cayman Investment Holdings L.p. 2201 Interest of corporation controlled by you
Tc Group Cayman Investment Holdings Sub L.p. 2201 Interest of corporation controlled by you
The Carlyle Group Inc. 2201 Interest of corporation controlled by you
Lin Feng
Mega Stream Limited
Trident Trust Company (hk) Limited 2301 Trustee
Ingenuity Capital Holdings Limited 2201 Interest of corporation controlled by you
Corelink Group Limited

Adicon Holdings (HKSE:09860) Headlines

No Headlines